Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
Abstract
Introduction:
This study involved a parallel comparison of the diagnostic and longitudinal monitoring potential of plasma glial fibrillary acidic protein (GFAP), total tau (t-tau), phosphorylated tau (p-tau181 and p-tau231), and neurofilament light (NFL) in preclinical Alzheimer's disease (AD).
Methods:
Plasma proteins were measured using Simoa assays in cognitively unimpaired older adults (CU), with either absence (Aβ−) or presence (Aβ+) of brain amyloidosis.
Results:
Plasma GFAP, t-tau, p-tau181, and p-tau231 concentrations were higher in Aβ+ CU compared with Aβ− CU cross-sectionally. GFAP had the highest effect size and area under the curve (AUC) in differentiating between Aβ+ and Aβ− CU; however, no statistically significant differences were observed between the AUCs of GFAP, p-tau181, and p-tau231, but all were significantly higher than the AUC of NFL, and the AUC of GFAP was higher than the AUC of t-tau. The combination of a base model (BM), comprising the AD risk factors, age, sex, and apolipoprotein E gene (APOE) ε4 status with GFAP was observed to have a higher AUC ( > 90%) compared with the combination of BM with any of the other proteins investigated in the current study. Longitudinal analyses showed increased GFAP and p-tau181 in Aβ+ CU and increased NFL in Aβ− CU, over a 12-month duration. GFAP, p-tau181, p-tau231, and NFL showed significant correlations with cognition, whereas no significant correlations were observed with hippocampal volume.
Discussion:
These findings highlight the diagnostic and longitudinal monitoring potential of GFAP and p-tau for preclinical AD.
RAS ID
38867
Document Type
Journal Article
Date of Publication
6-1-2022
Volume
18
Issue
6
Funding Information
Australian Alzheimer’s Research Foundation / Swedish Research Council,Grant / Award Number: #2018-02532 / European Research Council,Grant / Award Number: #681712 / Swedish State Support for Clinical Research, Grant / Award Number: #ALFGBG-720931 / Alzheimer Drug Discovery Foundation (ADDF), USA, Grant / Award Number: #201809-2016862, #RDAPB-201809-2016615 / UK Dementia Research Institute at UCL / Swedish Alzheimer Foundation, Grant / Award Number: #AF-742881 / Hjärnfonden, Sweden, Grant / Award Number: #FO2017-0243
PubMed ID
34494715
School
School of Medical and Health Sciences
Copyright
subscription content
Publisher
Wiley
Recommended Citation
Chatterjee, P., Pedrini, S., Ashton, N. J., Tegg, M., Goozee, K., Singh, A. K., Karikari, T. K., Simrén, J., Vanmechelen, E., Armstrong, N. J., Hone, E., Asih, P. R., Taddei, K., Doré, V., Villemagne, V. L., Sohrabi, H. R., Zetterberg, H., Masters, C. L., Blennow, K., & Martins, R. N. (2022). Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. DOI: https://doi.org/10.1002/alz.12447
Comments
Chatterjee, P., Pedrini, S., Ashton, N. J., Tegg, M., Goozee, K., Singh, A. K., ... & Martins, R. N. (2022). Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's & Dementia, 18(6), 1141-1154. https://doi.org/10.1002/alz.12447